Narrative review / 2015
D-allulose is a zero-calorie rare sugar that attenuates postprandial glucose levels in healthy and borderline diabetic subjects.
This review discusses the physiological functions and potential therapeutic role of the zero-calorie functional sweetener D-allulose in managing obesity and type 2 diabetes mellitus. Human trials cited in the review demonstrated that D-allulose attenuates postprandial glucose levels in healthy subjects and in individuals with borderline diabetes. In cell culture and animal models, D-allulose demonstrated anti-hyperlipidemic, anti-hyperglycemic, and anti-inflammatory properties, with rapid elimination in rat urine within 24 hours.
- Study type
- Narrative review
- Who was studied
- Healthy and borderline diabetic human subjects, as well as rodent and cell models
- What was measured
- Effects on postprandial glucose levels, obesity, and type 2 diabetes mellitus
THE PAPER
Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus.
Hossain A, Yamaguchi F, Matsuo T, Tsukamoto I, Toyoda Y, Ogawa M, Nagata Y, Tokuda M. Pharmacol Ther, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.